12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cornerstone Therapeutics, EKR deal

Cornerstone acquired EKR for $125 million in cash plus up to $25...

Read the full 39 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >